Canada markets close in 1 hour 14 minutes

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.75+0.53 (+1.81%)
As of 2:45PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close29.22
Open29.45
Bid29.72 x 1200
Ask29.74 x 900
Day's Range29.24 - 30.31
52 Week Range3.35 - 53.69
Volume651,490
Avg. Volume2,905,925
Market Cap5.902B
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateAug. 02, 2021 - Aug. 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.50
  • Pacific Biosciences Grants Equity Incentive Award to New Employee
    GlobeNewswire

    Pacific Biosciences Grants Equity Incentive Award to New Employee

    MENLO PARK, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock, and restricted stock units (“RSUs”) covering 40,000 shares of Pacific Biosciences common stock,

  • Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East, and Africa
    GlobeNewswire

    Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East, and Africa

    Industry Veteran Will Lead PacBio’s Commercial Footprint Across the RegionMENLO PARK, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today welcomed Neil Ward to the new role of Vice President and General Manager for the company’s Europe, Middle East, and Africa (EMEA) region to expand and develop the team and infrastructure to capitalize on the immense potential for genomics in

  • 2 Top Biotech Picks to Buy and Hold for the Next 10 Years
    Motley Fool

    2 Top Biotech Picks to Buy and Hold for the Next 10 Years

    For an investor focusing on the business, it might only be long enough to hear one quarterly update from management. To keep from getting whiplash, investors in Twist Bioscience (NASDAQ: TWST) and Pacific Biosciences of California (NASDAQ: PACB) will need to be focused on the long-term opportunity for synthetic DNA and long-read genome sequencing, respectively. Each company has a unique position in the life science industry, but short-term volatility could shake the confidence of anyone worried about the stock price over the next year or two.